Literature DB >> 24889168

MR imaging of diffuse liver disease: from technique to diagnosis.

Thomas A Hope1, Michael A Ohliger1, Aliya Qayyum2.   

Abstract

Over the past decade the role of MR imaging in the evaluation of diffuse liver disease has become common practice. Although detection of focal liver lesions remains the mainstay of liver imaging, a growing cohort of patients are referred for evaluation of hepatosteatosis, iron deposition diseases, and cirrhosis. In particular, multiecho sequences are becoming the gold standard for quantification of fat and iron. MR elastography allows for improved early detection of hepatic fibrosis. Unfortunately, a majority of the diffuse liver diseases lack specific features on MR imaging, yet a solid understanding of the different pathologic processes allows an informed interpretation. Published by Elsevier Inc.

Entities:  

Keywords:  Diffuse; Fat; Iron; Liver; MR imaging

Mesh:

Substances:

Year:  2014        PMID: 24889168     DOI: 10.1016/j.rcl.2014.02.016

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  10 in total

Review 1.  Advances in functional and molecular MRI technologies in chronic liver diseases.

Authors:  Iris Y Zhou; Onofrio A Catalano; Peter Caravan
Journal:  J Hepatol       Date:  2020-06-22       Impact factor: 25.083

2.  Radiomics nomograms based on R2* mapping and clinical biomarkers for staging of liver fibrosis in patients with chronic hepatitis B: a single-center retrospective study.

Authors:  Die Zhang; Yi Cao; Yi Sun; Xia Zhao; Cheng Peng; Jing Zhao; Xiaohui Bao; Lifei Wang; Chen Zhang
Journal:  Eur Radiol       Date:  2022-09-23       Impact factor: 7.034

Review 3.  Quantitative Imaging Biomarkers of NAFLD.

Authors:  Sonja Kinner; Scott B Reeder; Takeshi Yokoo
Journal:  Dig Dis Sci       Date:  2016-02-05       Impact factor: 3.199

4.  Diagnostic challenges in primary hepatocellular carcinoma: case reports and review of the literature.

Authors:  Monika Pazgan-Simon; Sylwia Serafinska; Justyna Janocha-Litwin; Krzysztof Simon; Jolanta Zuwala-Jagiello
Journal:  Case Rep Oncol Med       Date:  2015-04-01

5.  ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

Authors:  E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi
Journal:  Eur Radiol       Date:  2015-07-21       Impact factor: 5.315

6.  Nonalcoholic Fatty Liver Disease: Correlation of the Liver Parenchyma Fatty Acid with Intravoxel Incoherent Motion MR Imaging-An Experimental Study in a Rat Model.

Authors:  Seung-Man Yu; Sung Hwan Ki; Hyeon-Man Baek
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

7.  Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease.

Authors:  Mitsuko Inoue; Akinori Hayashi; Tomomi Taguchi; Riina Arai; Sayaka Sasaki; Koji Takano; Yusuke Inoue; Masayoshi Shichiri
Journal:  J Diabetes Investig       Date:  2019-01-04       Impact factor: 4.232

8.  Evaluation of Rabbits Liver Fibrosis Using Gd-DTPA-BMA of Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Authors:  Qian Cui; FengTai He; Jiawei Hu; Shuo Li; Dongmei Guo; Xu Bie; Wei Liu; Yiping Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-17       Impact factor: 2.629

Review 9.  Magnetic Resonance Imaging of Primary Hepatic Malignancies in Patients With and Without Chronic Liver Disease: A Pictorial Review.

Authors:  Lauren F Alexander; Peter Harri; Brent Little; Courtney C Moreno; Pardeep K Mittal
Journal:  Cureus       Date:  2017-08-04

Review 10.  Radiomics in liver diseases: Current progress and future opportunities.

Authors:  Jingwei Wei; Hanyu Jiang; Dongsheng Gu; Meng Niu; Fangfang Fu; Yuqi Han; Bin Song; Jie Tian
Journal:  Liver Int       Date:  2020-07-02       Impact factor: 5.828

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.